News & Press

News & Presskari.sharp@gmail.com2024-04-30T10:42:49-05:00

Press Releases

SkylineDx Publishes Landmark MERLIN_001 Trial in JAMA Surgery Validating the Predictive Power of the Merlin CP-GEP Test in Melanoma
Oct 22, 2025

Read More
SkylineDx’s Merlin Melanoma Assay shows its ability to reduce SLNB by over 40% in a Danish Multicenter Validation Study
Jul 22, 2025

Read More
SkylineDx Presents Landmark Findings from the Largest Prospective Multicenter Melanoma GEP trial at SSO 2025
Mar 28, 2025

Read More
Independent meta-analyses by Melanoma Institute of Australia on CP-GEP model in Melanoma Care
Oct 25, 2024

Read More
SkylineDx Announces Late-Breaking Data Presentation from The Largest Prospective Multi-Center Melanoma Gene Expression Profiling Trial at The 21st International Congress of the Society for Melanoma Research
Oct 13, 2024

Read More
SkylineDx Announces Presentation of New Data Highlighting the Predictive Power of the CP-GEP Merlin Test for T1a Cutaneous Melanoma Patients at the 21st International Congress of the Society for Melanoma Research
Oct 11, 2024

Read More
SkylineDx Announces Upcoming Oral Presentation at the 21st International Congress of the Society for Melanoma Research
Oct 8, 2024

Read More
SkylineDx Announces All Patients Enrolled in Landmark Study MERLIN_001, Advancing Melanoma Diagnostics
Jul 9, 2024

Read More
SkylineDx’s Merlin Assay stratifies Stage I/II cutaneous melanoma beyond SLNB for recurrence
May 30, 2024

Read More
Independent European data on CP-GEP model in Stratifying Melanoma Patients for Long Term Survival
Apr 5, 2024

Read More
Independent validation of performance Merlin Test in Swedish patients
Mar 24, 2024

Read More
Melanoma risk prediction of nodal metastasis and long-term survival outcome by CP-GEP model in a U.S. cohort
Mar 8, 2024

Read More
SkylineDx Announces Grant of European Patent and Advances in Melanoma Diagnosis and Treatment
Jan 9, 2024

Read More
SkylineDx Announces Commercial Collaboration with Tempus to Advance Patient Care with its Merlin™ Test
Dec 5, 2023

Read More
Multicenter US Study Reveals CP-GEP’s Profound Impact on Stratifying Melanoma Patients for Long-Term Survival
Nov 6, 2023

Read More